UiPath Inc. (NYSE:PATH) Shares Purchased by Toronto Dominion Bank

Toronto Dominion Bank increased its stake in UiPath Inc. (NYSE:PATH) by 15.4% in the second quarter, Holdings Channel reports. The firm owned 42,654 shares of the healthcare company’s stock after purchasing an additional 5,704 shares during the period. Toronto Dominion Bank’s holdings in UiPath were worth $541,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of PATH. Vanguard Group Inc. lifted its stake in shares of UiPath by 5.6% during the first quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after buying an additional 2,133,078 shares during the period. State Board of Administration of Florida Retirement System raised its stake in UiPath by 0.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 295,370 shares of the healthcare company’s stock worth $6,696,000 after acquiring an additional 1,571 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in UiPath by 3,389.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 89,189 shares of the healthcare company’s stock worth $1,131,000 after acquiring an additional 86,633 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its stake in UiPath by 4.2% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 231,694 shares of the healthcare company’s stock valued at $5,240,000 after purchasing an additional 9,393 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in UiPath by 245.1% during the 1st quarter. Acadian Asset Management LLC now owns 45,700 shares of the healthcare company’s stock valued at $1,032,000 after purchasing an additional 32,456 shares during the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Stock Performance

Shares of PATH stock opened at $12.79 on Tuesday. UiPath Inc. has a fifty-two week low of $10.37 and a fifty-two week high of $27.87. The stock has a market capitalization of $7.33 billion, a P/E ratio of -79.94 and a beta of 0.87. The company has a 50 day moving average price of $12.17 and a 200 day moving average price of $15.36.

UiPath (NYSE:PATH) last announced its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The business had revenue of $316.00 million during the quarter, compared to the consensus estimate of $303.69 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, research analysts forecast that UiPath Inc. will post -0.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.07, for a total transaction of $575,388.97. Following the sale, the chief financial officer now owns 849,917 shares of the company’s stock, valued at $10,258,498.19. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 22.37% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PATH shares. BMO Capital Markets lifted their target price on UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a report on Friday, September 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $16.00 target price on shares of UiPath in a research report on Friday, September 6th. Needham & Company LLC reissued a “hold” rating on shares of UiPath in a research note on Friday, September 6th. Macquarie lowered shares of UiPath from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $29.00 to $12.00 in a research note on Monday, June 3rd. Finally, Wells Fargo & Company boosted their price target on shares of UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Friday, September 6th. Sixteen equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $17.71.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.